Trevor Allred
Stock Analyst at Oppenheimer
(4.88)
# 287
Out of 4,456 analysts
42
Total ratings
93.1%
Success rate
84.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $210 | $148.21 | +41.69% | 7 | May 21, 2026 | |
| DNTH Dianthus Therapeutics | Rated: Hold | n/a | $95.35 | - | 7 | May 11, 2026 | |
| BBIO BridgeBio Pharma | Rated: Hold | n/a | $70.24 | - | 10 | May 11, 2026 | |
| TBPH Theravance Biopharma | Downgraded: Hold | $27 → $14 | $17.63 | -22.46% | 2 | Mar 5, 2026 | |
| INVA Innoviva | Downgraded: Buy | $35 | $23.57 | +48.49% | 3 | Feb 26, 2026 | |
| LGND Ligand Pharmaceuticals | Maintained: Buy | $250 → $275 | $303.59 | -9.42% | 9 | Nov 7, 2025 | |
| MBX MBX Biosciences | Maintained: Buy | $38 → $80 | $52.31 | +52.93% | 4 | Nov 7, 2025 |
Palvella Therapeutics
May 21, 2026
Reiterated: Buy
Price Target: $210
Current: $148.21
Upside: +41.69%
Dianthus Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $95.35
Upside: -
BridgeBio Pharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $70.24
Upside: -
Theravance Biopharma
Mar 5, 2026
Downgraded: Hold
Price Target: $27 → $14
Current: $17.63
Upside: -22.46%
Innoviva
Feb 26, 2026
Downgraded: Buy
Price Target: $35
Current: $23.57
Upside: +48.49%
Ligand Pharmaceuticals
Nov 7, 2025
Maintained: Buy
Price Target: $250 → $275
Current: $303.59
Upside: -9.42%
MBX Biosciences
Nov 7, 2025
Maintained: Buy
Price Target: $38 → $80
Current: $52.31
Upside: +52.93%